Alzheimers Research & Therapy

Alzheimer's Research & Therapy is a peer-reviewed open access journal published by BMC, part of Springer Nature, founded in 2009 and devoted to translational research into Alzheimer's disease and other neurodegenerative diseases, with a 2025 Journal Impact Factor of 8.9《阿尔茨海默病研究与治疗》（Alzheimer's Research & Therapy）是由（BMC）出版的同行评审开放获取期刊，隶属（Springer Nature），2009 年创办，专注阿尔茨海默病及其他神经退行性疾病的转化研究，2025 年影响因子为 8.9。

Scope

• The journal is the major forum for translational research into Alzheimer's disease该刊是阿尔茨海默病转化研究的主要论坛。
• It publishes open access basic research with a translational focus, as well as clinical trials它发表具有转化导向的开放获取基础研究，以及临床试验。
• Further content includes research into drug discovery and development and epidemiologic studies其他内容还包括药物发现与开发研究以及流行病学研究。
• Although the primary focus is Alzheimer's disease, the scope covers translational research into other neurodegenerative diseases尽管主要聚焦阿尔茨海默病，其范围也涵盖其他神经退行性疾病的转化研究。
• The journal also provides reviews, viewpoints, commentaries, debates and reports该刊还提供综述、观点、评论、辩论与报告。
• It is affiliated with Alzheimer's Disease International and ranks in the first quartile of the Clinical Neurology category该刊与（Alzheimer's Disease International）保持合作，位居临床神经病学类的第一四分位。

History

• The journal was launched in 2009, with its first editorial published in July that year该刊于 2009 年创刊，首篇社论于当年 7 月发表。
• Its founding editors-in-chief were Doug Galasko, Todd Golde and Gordon Wilcock其创刊主编为（Doug Galasko）、（Todd Golde）与（Gordon Wilcock）。
• It is published by BMC under Springer Nature and operates a single-blind peer review system该刊由（Springer Nature）旗下的（BMC）出版，实行单盲同行评审。
• All articles become freely accessible online on publication and are covered by a Creative Commons Attribution license所有文章一经发表即可在线免费获取，采用知识共享署名许可。
• Authors pay an article processing charge of GBP 2790, USD 3990 or EUR 3190, subject to local taxes作者需支付文章处理费 2790 英镑、3990 美元或 3190 欧元，另加当地税费。
• Its Journal Impact Factor rose from 6.982 in 2021 to 8.823 in 2022, stood at 7.6 in 2024 and reached 8.9 in 2025其影响因子由 2021 年的 6.982 升至 2022 年的 8.823，2024 年为 7.6，2025 年达到 8.9。
• A decade review by its editors reflected on the journal's first ten years of translational dementia research该刊编辑撰写的一篇十年回顾总结了其转化型痴呆研究的头十年。^[1]

Editors

• The editors-in-chief are Delphine Boche of the University of Southampton and Kristian Steen Frederiksen of the University of Copenhagen联席主编为（University of Southampton）的（Delphine Boche）与（University of Copenhagen）的（Kristian Steen Frederiksen）。
• Charlotte Teunissen of Amsterdam UMC is the third editor-in-chief and works on biomarkers第三位主编为（Amsterdam UMC）的（Charlotte Teunissen），从事生物标志物研究。
• Miia Kivipelto of the Karolinska Institute serves as deputy editor副主编为（Karolinska Institute）的（Miia Kivipelto）。
• The associate editors include researchers from University College London, INSERM, the University of Gothenburg and Cleveland Clinic副编辑包括来自（University College London）、（INSERM）、（University of Gothenburg）与（Cleveland Clinic）的研究者。
• The editorial board is international, with members in Sweden, the United States, China, Italy and other countries编委会成员国际化，分布于瑞典、美国、中国、意大利等国家。
• Submissions are handled online, and the journal offers rapid peer review with an average time to first decision of about five weeks稿件在线提交，该刊提供快速同行评审，初审平均约需五周。